Zacks Investment Research on MSN
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...
Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback